Interleukin 17 Production Among Patients with American Cutaneous Leishmaniasis

Citation

Olívia Bacellar, Daniela Faria, Márcia Nascimento, Thiago M. Cardoso, Kenneth J. Gollob, Walderez O. Dutra, Phillip Scott, Edgar M. Carvalho, Interleukin 17 Production among Patients with American Cutaneous Leishmaniasis, The Journal of Infectious Diseases, Volume 200, Issue 1, 1 July 2009, Pages 75–78, https://doi.org/10.1086/599380

Abstract

Interleukin 17 (IL-17) plays a critical role in inflammation and autoimmunity. Very little is known about IL-17 in protozoa infection. Here, we show that lymphocytes obtained from patients with mucosal leishmaniasis and cutaneous leishmaniasis produce higher levels of IL-17 than do lymphocytes obtained from uninfected control subjects (⁠P<.01⁠). There was a tendency for tissue obtained from patients with mucosal leishmaniasis to contain a higher number of cells expressing IL-17, compared with tissue obtained from patients with cutaneous leishmaniasis, and there was a direct correlation between the number of cells expressing IL-17 and the presence of cellular inflammation at the lesion site (⁠r2=0.86⁠; P<.001⁠). These data support the role of IL-17 in the pathogenesis of the inflammatory reaction in leishmaniasis.

Keywords: inflammation, cutaneous leishmaniasis, autoimmunity, interleukin-17, leishmaniasis, lymphocytes, infections, protozoa, mucosal leishmaniasis


Read more from SRI

  • A photo of Mary Wagner

    Recognizing the life and work of Mary Wagner 

    A cherished SRI colleague and globally respected leader in education research, Mary Wagner leaves behind an extraordinary legacy of groundbreaking work supporting children and youth with disabilities and their families.

  • Testing XRGo in a robotics laboratory

    Robots in the cleanroom

    A global health leader is exploring how SRI’s robotic telemanipulation technology can enhance pharmaceutical manufacturing.

  • SRI research aims to make generative AI more trustworthy

    Researchers have developed a new framework that reduces generative AI hallucinations by up to 32%.